Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CRSP
CRSP logo

CRSP News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CRSP News

CRISPR Therapeutics' Financing Plan Triggers Stock Price Drop

3h agoFool

CRISPR Therapeutics Issues Debt to Advance Drug Portfolio

3h agoNASDAQ.COM

CRISPR Therapeutics to Issue $350 Million Convertible Notes

6h agoBenzinga

CRISPR Therapeutics Plans $350 Million Private Debt Offering

10h agostocktwits

CRISPR Therapeutics Plans $350 Million Convertible Notes Offering

10h agoNASDAQ.COM

TD Cowen Upgrades Rivian to Buy, Raises Price Target

11h agostocktwits

S&P 500 Futures Hold Steady in Pre-Market Session; Vertex Pharmaceuticals and UFP Industries Take the Lead

12h agoBarron's

CRISPR Therapeutics to Offer $350M Convertible Senior Notes

12h agoseekingalpha

CRSP Events

03/10 16:20
Major Averages Close Little Changed as Oil Prices Pull Back
The major averages closed little changed as markets traded with a more constructive tone in concert with oil prices pulling back. Oil prices, which had surged above $100 and briefly approached $120 per barrel during the escalation of the Iran conflict, are now coming back in after comments from Donald Trump suggesting the military operation could conclude sooner than previously expected. Meanwhile, CBS News' Jennifer Jacobs reported that there are indications Iran is taking steps to deploy mines in the Strait of Hormuz.In other commodity news, gold prices continue their surge amid market volatility. Despite having an up-and-down 2026, the commodity is climbing towards record highs once again.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiaand Thinking Machines Lab announced a gigawatt-scale strategic partnershipBioNTechannounced plans for anto be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Ozlem Tureci, M.D.HP Enterprisereportedand provided guidance for Q1 and FY26Kohl'sreportedbut guided for a decrease in Q1 comp salesVail Resortsreportedand cut its FY26 resort reported EBITDA view2. WALL STREET CALLS:Qualcommat Underperform at BofACrowdStriketo Overweight at Morgan StanleyRivianto Buy at TD Cowen into R2 launchNovo Nordiskto Hold at TD CowenB. RileyStrategywith Buy on "unmatched scale"3. AROUND THE WEB:Boeingwill delay deliveries of some e737 MAX planes amid wiring flaws, WSJ reportsExxon Mobilis planning to move its legal home to Texas from New Jersey in a move meant to protect the company from shareholder "abuse," WSJ saysRio Tintois in talks with Mongolia over financial terms at the massive Oyu Tolgoi copper mine, with the government seeking lower loan interest costs and the removal of Rio's annual management fee, WSJ reportsAppleincreased its iPhone production in India by 53% last year and now makes a total of 25% of its devices there, Bloomberg saysAmazon'secommerce business has requested a large group of engineers to meet on Tuesday for a "deep dive" into the influx of outages, with the company stating there has been a "trend of incidents" characterized by a "high blast radius" and "Gen-AI assisted changes," FT reports4. MOVERS:Zevra Therapeuticsgains after, with EPS and revenue beating consensusCapricorincreases after announcing the establishment of a new PDUFANiohigher in New York afterand providing guidance for Q1Centenefalls afterand announcing its ACA enrollment is "still in line" with expectations"Crispr Therapeuticslower after announcing a5. EARNINGS/GUIDANCE:ABM, with CEO Scott Salmirs commenting, "ABM is off to a solid start to FY26"Custom Truck One Source, with EPS beating consensusUnited Natural Foodsand provided guidance for FY26UWM Holdingsraised itsPriority Technologyand provided guidance for FY26INDEXES:The Dow fell 34.29, or 0.072%, to 47,706.51, the Nasdaq gained 1.16, or 0.0051%, to 22,697.10, and the S&P 500 advanced 14.51, or 0.21%, to 6,781.48.
03/10 12:10
Crispr Therapeutics Stock Falls 9.2% to $53.40
Crispr Therapeutics is down -9.2%, or -$5.38 to $53.40.
03/10 12:00
Major Averages Rise as Oil Prices Retreat Below $100
The major averages were higher near noon as markets are trading with a more constructive tone. Investors are reacting to a reversal in the energy shock that dominated markets earlier in the week. Oil prices, which had surged above $100 and briefly approached $120 per barrel during the escalation of the Iran conflict, are now pulling back after comments from Donald Trump suggesting the military operation could conclude sooner than previously expected.Meanwhile, gold prices continue their surge amid market volatility, as the "safe haven" asset rose nearly 2%. Despite having an up-and-down 2026, the commodity is climbing towards record highs once again.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiaintends to launch an open-source AI agent platform,BioNTechannounced plans forto be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Ozlem Tureci, M.D.HP Enterprisereportedand provided guidance for Q1 and FY26Kohl'sreportedbut guided for a decrease in Q1 comp salesVail Resortsreportedand cut its FY26 resort reported EBITDA view2. WALL STREET CALLS:Qualcommat Underperform at BofACrowdStriketo Overweight at Morgan StanleyRivianto Buy at TD Cowen into R2 launchNovo Nordiskto Hold at TD CowenB. RileyStrategywith Buy on "unmatched scale"3. AROUND THE WEB:Exxon Mobilis planning to move its legal home to Texas from New Jersey in a move meant to protect the company from shareholder "abuse," WSJ saysRio Tintois in talks with Mongolia over financial terms at the massive Oyu Tolgoi copper mine, with the government seeking lower loan interest costs and the removal of Rio's annual management fee, WSJ reportsAppleincreased its iPhone production in India by 53% last year and now makes a total of 25% of its devices there, Bloomberg saysAmazon'secommerce business has requested a large group of engineers to meet on Tuesday for a "deep dive" into the influx of outages, with the company stating there has been a "trend of incidents" characterized by a "high blast radius" and "Gen-AI assisted changes," FT reportsA groundstop for all JetBlueflights was canceled within an hour on Tuesday by the U.S. Federal Aviation Administration, FAA, after JetBlue said it resolved a "system outage," Reuters reports4. MOVERS:Zevra Therapeuticsgains after, with EPS and revenue beating consensusCapricorincreases after announcing the establishment of afor dermiocel BLANiohigher in New York afterand providing guidance for Q1Centenefalls afterfor FY26 and announcing its ACA enrollment is "still in line" with expectations"Crispr Therapeuticslower after announcing a5. EARNINGS/GUIDANCE:ABM, with CEO Scott Salmirs commenting, "ABM is off to a solid start to FY26"Custom Truck One Source, with EPS beating consensusUnited Natural Foodsand provided guidance for FY26UWM Holdingsfor Q1Priority Technologyand provided guidance for FY26INDEXES:Near midday, the Dow was up 0.48%, or 229.12, to 47,969.92, the Nasdaq was up 0.58%, or 131.24, to 22,827.19, and the S&P 500 was up 0.39%, or 26.81, to 6,822.80.
03/10 07:20
CRISPR Therapeutics to Offer $350M Convertible Senior Notes in Private Placement
CRISPR Therapeutics announced its intention to offer, subject to market conditions and other factors, $350M aggregate principal amount of its convertible senior notes due 2031 in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Company also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $52.5M aggregate principal amount of the notes. The notes will be senior, unsecured obligations of the Company and will accrue interest payable semiannually in arrears on March 1 and September 1 of each year, beginning on September 1, 2026. The notes will mature on March 1, 2031, unless earlier converted, redeemed or repurchased. Upon conversion, the Company will deliver common shares, nominal value CHF 0.03 per share. The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering. The Company intends to use the net proceeds from the offering for general corporate purposes.

CRSP Monitor News

CRISPR Therapeutics Announces $350 Million Debt Offering

Mar 10 2026

CRISPR Therapeutics Rises Amid Acquisition Speculation

Feb 26 2026

CRISPR Therapeutics Stock Rises Despite Poor Q4 Earnings

Feb 13 2026

CRISPR Therapeutics sets milestones for 2026 despite stock decline

Feb 05 2026

CRISPR Therapeutics Faces Pressure from Insider Sales and Weak Revenue

Jan 30 2026

CRISPR Therapeutics faces stock decline amid market trends

Jan 23 2026

Ark Invest highlights genomics potential, benefiting CRISPR Therapeutics

Jan 22 2026

CRISPR Therapeutics AG Rises Following Positive Clinical Updates

Jan 06 2026

CRSP Earnings Analysis

No Data

No Data

People Also Watch